Engflag

Atg-S

Quick links to important sections

Atg-S

Atg-S_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atg-S

What is Atg-S? (Antithymocyte Immunoglobulin Rabbit)

Property Description
Active ingredient Antithymocyte Globulin (Rabbit)
Form Lyophilized powder for intravenous solution
Pharmacological class Immunosuppressant Agent, T-cell Depleting Agent
Common use Achieving rapid immune suppression
Origin Xenotypic protein (derived from rabbit plasma)

What Type of Medicine is Atg-S? (Definition and Classification)

Atg-S is a potent biological medicine that functions as an immunosuppressant agent, specifically categorized as a T-cell depleting agent. Its active pharmacological substance is Antithymocyte Globulin (Rabbit), a highly purified polyclonal antibody preparation.

The drug belongs to the class of Immune Globulins. Its polyclonal nature is a differentiating feature from newer, single-target synthetic biologics, as it allows the preparation to contain a diverse array of antibodies capable of binding to multiple T-cell surface antigens. This broad binding action ensures a consistently profound capacity to modulate the immune system, which is essential for its high-level therapeutic application in conditions requiring rapid immune control.

Composition, Origin, and Pharmaceutical Form

The medicine is characterized as a xenotypic protein, meaning it is a foreign protein derived from a non-human source, specifically the plasma of rabbits that were immunized with human thymocytes. This process results in the concentration of purified Antithymocyte Immunoglobulins.

The manufacturing process yields the product as a sterile lyophilized powder in a vial, which requires reconstitution into a specialized solution for infusion, and its administration is strictly via the intravenous route. The necessity for intravenous delivery is linked directly to the large size and protein nature of the active molecule, which would otherwise be rapidly degraded and ineffective if delivered orally.

General Purpose and Action of this Immunosuppressant Agent

The primary general purpose of Atg-S is to rapidly achieve a state of intense immune suppression by targeting the immune system's most active cells. It achieves this through its antibodies, which "tag" circulating T-lymphocytes (T-cells) for immediate removal from the bloodstream.

This binding action leads to a rapid and substantial reduction, known as T-cell depletion. By eliminating these key immune conductors, the medicine temporarily minimizes the risk of the body mounting a vigorous immune response against foreign material, thereby creating a necessary "quiet" immune environment to facilitate critical medical procedures.

What side effects are possible with Atg-S?

Possible Side Effects and Safety Information

The safety profile of Antithymocyte Globulin (Rabbit) (Atg-S) is consistent with its function as a potent immunosuppressant and xenotypic protein, as defined by official regulatory documentation. Adverse reactions are classified based on frequency and impact on physiological systems.

Frequency-Classified Adverse Reactions

Official safety data categorizes numerous effects as very common, meaning they affect more than 1 in 10 patients. These include fever (pyrexia), chills, leukopenia (low white blood cell count), hyperkalemia (high blood potassium), and urinary tract infection. Effects are grouped across several System-Organ Classes, such as Blood and Lymphatic System Disorders and Infections and Infestations.

Serious Adverse Reactions and Constraints

The label documents the risk of serious adverse reactions, including anaphylaxis (a severe, life-threatening allergic reaction), severe Cytokine Release Syndrome (CRS), sepsis (severe infection), and an increased risk of malignancy such as Lymphoproliferative Disorders (LPD). The drug is contraindicated in patients with a history of allergy to rabbit proteins or those with active acute or chronic infections.

Time-Related Safety Patterns

Certain effects have a specific timing pattern. Infusion-Associated Reactions may occur during or immediately following administration. A delayed reaction consistent with serum sickness, involving symptoms like joint pain, may appear 5 to 15 days after the infusion. Use requires careful management of concomitant immunosuppressive therapies to avoid over-immunosuppression.

Overdose and Emergency Response

Overdose Manifestations and Complications

The official regulatory profile for Antithymocyte Globulin (Rabbit) (Atg-S) defines overdosage by its primary documented physiological effects. Overexposure may result in significant hematologic toxicity, specifically leukopenia (a low white blood cell count, including lymphopenia and neutropenia) and thrombocytopenia (a low platelet count). These abnormalities are the principal clinical presentations associated with overdosage.

The regulatory labeling also highlights the potential for life-threatening outcomes during administration that mandate immediate action, such as Fatal Anaphylaxis and Severe acute Cytokine Release Syndrome (CRS). Severe CRS is documented to cause serious cardiorespiratory events and may lead to death.

Emergency Action and Management

If overdosage is suspected, individuals must seek immediate medical attention or contact emergency services at once. The regulatory profile confirms that no specific antidote is known for Atg-S overdosage.

For managing the documented hematologic toxicity, the protocol requires dose reduction. If a severe acute reaction occurs, the infusion must be terminated immediately, and resuscitative measures (including epinephrine, oxygen, and other emergency treatments) must be readily available and initiated. Total white blood cell and platelet counts are required to be monitored closely to guide appropriate management.

Therapeutic Uses of Atg-S

What Atg-S Treats: Main Uses and Benefits

Atg-S is commonly applied in critical clinical situations when patients experience acute and challenging symptom patterns that stem from a misdirected immune system. Its use is generally considered relevant in clinical settings marked by heightened physiological stress where supportive symptom management is appropriate.

Easing Symptoms Related to Organ Rejection

This medication is commonly used when patients present with Organ Rejection Indicators—symptoms that cluster when the body’s immune system attempts to attack a newly transplanted organ. This therapy is considered relevant in support in addressing allograft rejection in renal transplant patients. It is applied during episodes of sudden symptom escalation following a transplant. The key therapeutic benefit is that it offers symptomatic relief that supports the newly transplanted organ by easing symptomatic strain and contributes to improved comfort during this critical phase.

“This medication is used as part of the supportive care strategy to help manage the body’s response to transplanted tissue.”

Quick Fact: Relief for Symptoms Related to Immune System Overactivity

Addressing Symptom Burden in Severe Blood Disorders

Atg-S is also used to address Immune Cell Deficiency Symptoms, which are disruptive manifestations like intense fatigue, increased vulnerability to infections, or unusual bruising, associated with certain severe blood disorders such as aplastic anemia. It is applicable in conditions marked by heightened symptoms of blood cell loss. By providing short-term symptomatic assistance, it helps the bone marrow recover and contributes to easing the overall symptom load during these difficult episodes.

Regulatory References

  1. FDA's prescribing information for a type of Antithymocyte Globulin

Eligibility and Restrictions for Use

The eligibility for Antithymocyte Globulin (Rabbit) (Atg-S) is strictly defined by regulatory documents, focusing on absolute exclusions and population-specific restrictions.

Populations for Whom Use is Contraindicated

This medicine is contraindicated and must not be used in specific patient groups, based on official labeling from regulatory authorities:

  • Hypersensitivity: Patients with a documented history of allergy or anaphylaxis to rabbit proteins or to any product components.
  • Active Infection: Patients with active acute or chronic infections which would prohibit any additional immunosuppressive therapy.

Condition-Specific and Age-Related Eligibility

Category Regulatory Status
Age (Adults) Standard approved population for kidney transplant indications.
Age (Pediatric) Safety and efficacy have not been established in children in controlled clinical trials.
Renal/Hepatic Impairment No dose adjustment is necessary, allowing standard use in these conditions.
Pregnancy Use is conditional: only if the potential benefit justifies the risk to the fetus.
Lactation Breastfeeding should be discontinued during treatment.

Eligibility-related restrictions also state that immunization with attenuated live vaccines is not recommended for patients who have recently received Atg-S.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory documents define the interaction profile for Antithymocyte Globulin (Rabbit) (Atg-S) based on its profound immune-modulating action, leading to specific categorical risks rather than common metabolic drug-drug interactions. The official information is structured around identifying high-risk combinations and mandatory timing restrictions.

Documented Interaction Restrictions and Risks

Classification Interacting Product / Condition Official Outcome / Restriction
Formal Contraindication Rabbit Proteins (allergy history) Co-administration is formally prohibited in individuals with a known history of allergy or anaphylactic reaction to rabbit-derived components.
Formal Contraindication Active Acute or Chronic Infections The use of Atg-S is prohibited in patients who have active infections, as further immune suppression is contraindicated by regulatory bodies.
Pharmacodynamic Risk Other Immunosuppressive Agents Co-administration with other immunosuppressants (such as maintenance regimen drugs) results in an officially documented increased risk of infection and potential for malignancy (e.g., lymphoproliferative disorders).
Timing Restriction Attenuated Live Vaccines Immunization with these biological products is not recommended for patients who have recently received Atg-S due to potential ineffective immunization and safety concerns.

Pharmacokinetic and Substance Interactions

The large protein structure of this medicine means the official regulatory labels do not specify involvement with typical small-molecule clearance pathways. Consequently, there are no documented interactions in official prescribing information related to CYP enzymes or drug transporters (P-gp, OATP, BCRP). Furthermore, official regulatory documents do not explicitly cite specific interactions with common substances such as food, alcohol, or herbal products. The lack of documented metabolic interactions is consistent with the drug's classification and biological nature.

Mechanism of Action

Molecular Tagging and T-Cell Lysis

The core mechanism of Antithymocyte Globulin (Rabbit) (Atg-S) involves the specific and comprehensive binding of polyclonal antibodies to numerous surface markers, including CD3, on circulating T-lymphocytes (T-cells). This tagging immediately initiates a cytotoxic cascade: the activation of the complement pathway physically ruptures the cells, while opsonization marks them for rapid clearance by macrophages in the spleen and liver. This dual molecular action results in a rapid and substantial depletion of the T-lymphocyte population.

Functional Blockade and Immune Quiescence

Beyond cell destruction, the mechanism includes functional modulation where the antibodies bind to T-cell adhesion molecules, such as Integrins. This interaction prevents the remaining T-cells from adhering to blood vessel walls, thereby disrupting leukocyte trafficking and blocking their ability to migrate into tissues to initiate or sustain a localized immune response. This mechanism contributes to a state of systemic immune quiescence, resulting from both cell removal and functional inhibition.

Active Immunomodulation and Mechanistic Limits

The mechanism also involves a longer-term immunomodulatory component: the antibodies promote the expansion of Regulatory T cells ( Tregs), a population that actively suppresses other effector T-cells, contributing to immune tolerance. However, the resulting suppression is inherently temporary because the drug does not target T-cell production in the thymus, allowing the T-cell population to gradually reconstitute over time, which defines the constraint of the mechanism.

Dosage and Administration Information

How Atg-S is Used: Official Administration Guidelines

Atg-S (Antithymocyte Globulin [Rabbit]) is administered strictly by intravenous infusion under mandatory medical supervision in a hospital setting, reflecting the complexity of its preparation and administration. The medicine is provided as a lyophilized powder that must be reconstituted with Sterile Water for Injection, then further diluted in an infusion solution, and passed through a 0.22 μm in-line filter prior to administration.

Dosing Regimens and Schedule

Official dosing is calculated based on body weight, typically 1.5 mg/kg per day for indications related to kidney transplantation, including both prophylactic use and the treatment of acute rejection. For severe blood disorders, such as aplastic anemia, the dose is generally higher, ranging from 2.5 to 3.5 mg/kg daily. The drug is given on a daily schedule for a set duration:

  • Kidney Prophylaxis: 4 to 7 consecutive days.
  • Acute Rejection Treatment: 7 to 14 consecutive days.
  • Aplastic Anemia: 5 consecutive days.

Procedural Administration and Adjustments

To manage administration, the first daily dose must be infused slowly over a minimum of 6 hours, with subsequent doses taking at least 4 hours. The official instructions provide non-negotiable rules for dose modification or interruption. Specifically, if blood cell counts (platelets or white blood cells) fall below predetermined threshold numbers, the dose must be reduced by one-half or withheld entirely to manage the standardized use protocol. Dosage recommendations for older adults and patients with renal or hepatic impairment are generally the same as those for other adults, but dosing for obese patients should be calculated using their ideal body weight.

Recent Clinical Evidence

Research Evidence for Atg-S

The research evidence for Antithymocyte Globulin (Rabbit) (Atg-S) primarily derives from Randomized Controlled Trials (RCTs) and long-term observational cohort studies across its main uses.

Evidence in Organ Transplantation

For treating acute organ transplant rejection, RCTs and systematic reviews examine outcomes such as the frequency of biopsy-proven acute rejection (BPAR) events and patient and graft survival. Studies tracked how these outcomes evolved in patients who received Atg-S, reporting measurements of kidney function markers during follow-up. However, long-term data on organ function for all subgroups are not fully established, and research comparing Atg-S to certain newer immunosuppressive agents is limited.

As transplant induction therapy (prevention of rejection), Atg-S was evaluated through RCTs in high-risk patients, monitoring the incidence of BPAR and delayed graft function (DGF). Long-term research is ongoing to establish survival measurements for various induction agents.

Evidence in Severe Blood Disorders

In severe blood disorders like aplastic anemia, the evidence base includes RCTs, often evaluating Atg-S in combination with other agents, focusing on hematologic response (specific improvement in blood cell counts) and overall survival. Long-term studies track survival and the risk of relapse or disease progression. Evidence quality varies due to differences in how hematologic response is defined across trials, and data for certain patient groups remain insufficient.

Research Gaps and Uncertainty

Overall, the evidence highlights patterns observed in study populations, but results apply only to those groups. The follow-up durations were limited in specific trials, meaning there is limited information for long-term outcomes and durability of response across all indications. Findings describe group patterns, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Rabbit-Derived Antithymocyte Globulin-Associated Perioperative Anaphylaxis in Renal Transplantation: A Multidisciplinary Perspective on Pathophysiology, Clinical Presentation, and Management (Review covering key RCTs and long-term follow-up)
  2. The role of rabbit antithymocyte globulin in renal transplantation (Review summarizing induction and rejection treatment efficacy)
  3. Thymoglobulin® (Anti-thymocyte Globulin [Rabbit]) Product Monograph (Regulatory/Labeling information for approved indications)

Frequently Asked Questions (FAQ)

Common questions about Atg-S (FAQ)

Q: How long does it typically take for Atg-S to start working?

A: According to official product information, the drug’s mechanism of action involves the rapid and substantial depletion of the circulating T-lymphocyte population (a type of immune cell). This process is defined as rapid in official documents. However, the time it takes for a patient to experience the full clinical benefit (the effect on their condition) can vary.

Q: How does Atg-S compare to similar treatments that are available?

A: Regulatory documents classify Atg-S as a polyclonal antibody preparation. This means it contains a diverse mix of antibodies that bind to multiple targets on T-cells. This polyclonal nature is what differentiates it from newer, synthetic biologics that are designed to target only a single marker on these cells.

Q: Can I take Atg-S if I also take Tylenol (acetaminophen) or ibuprofen?

A: The drug is not known to interact with common metabolic pathways in the body. Official instructions indicate that a drug like acetaminophen (paracetamol) is often administered before the infusion begins, which is a procedure documented in the administration process to help manage potential infusion-associated reactions. Official documents do not typically cite specific information regarding ibuprofen.

Q: Is it common to feel tired when starting Atg-S?

A: Official safety data lists adverse reactions such as headache and dizziness, which may contribute to a general feeling of being unwell. While feeling tired is not itself consistently listed as a 'very common' effect, the appearance of new symptoms is typically reported to the medical team managing the treatment.

Q: Why do some people report feeling worse before they feel better on Atg-S?

A: Temporary feelings of being unwell are often related to expected adverse reactions defined in the official information. These include Infusion-Associated Reactions that occur during or right after the dose, and a delayed reaction known as serum sickness which can start 5 to 15 days after treatment is complete. These reactions typically include symptoms like fever or chills.

Q: What should I do if a side effect feels serious?

A: The administration of Atg-S requires the patient to be under strict medical supervision in a hospital setting. Any concern about a serious side effect is typically reported to the medical team immediately, as they are present to manage adverse events.

Q: What is the maximum duration Atg-S has been studied for continuous use?

A: Official dosing guidelines define the longest continuous course of treatment in trials as up to 14 consecutive days for treating acute rejection of a transplanted organ. The treatment duration varies based on the specific condition being addressed.

Q: Can I stop taking Atg-S suddenly, or do I need to taper off?

A: The official treatment schedule dictates a fixed, short duration of daily administration. The infusion is only interrupted or the dose reduced if the patient’s blood cell counts drop below official threshold numbers. Completing the course of treatment does not typically require a tapering off schedule.

Q: Is Atg-S used for anything besides the main condition?

A: The official uses of Atg-S are defined by regulatory agencies. These indications relate to managing the immune system in the context of kidney transplantation (to prevent or treat rejection) and in the treatment of certain severe blood disorders, such as aplastic anemia.

Q: Does Atg-S interact with caffeine or energy drinks?

A: The official regulatory documents do not specifically cite interactions with caffeine, energy drinks, or food. This is consistent with the drug's classification, as its large protein structure does not typically involve the major metabolic pathways responsible for most common food-drug interactions.

Q: Is Atg-S safe for people over 65 years old?

A: Official product information states that dosage recommendations for older adults are generally the same as those for other adults. Official documentation does not note a need for specific dose adjustment for this age group.

Q: Do I need any special tests before starting Atg-S?

A: Official procedures require regular monitoring of blood cell counts (specifically platelets and white blood cells) to ensure proper dosing throughout treatment. Furthermore, official information indicates that skin testing may be used to assess the patient's risk of allergy before starting the infusion.

Q: Are there different versions or brands of Atg-S available?

A: Different approved products containing anti-thymocyte globulin (ATG) exist. These products are not considered interchangeable. The official dose must be specifically calculated based on the particular product that is being administered to the patient.

Q: Is Atg-S considered a 'high-risk' medicine?

A: The medicine is officially classified as a potent immunosuppressant and a T-cell depleting agent. Due to its powerful effect on the immune system, regulatory documents detail the risk of serious reactions, including a severe allergic reaction (anaphylaxis), serious infection (sepsis), and the potential for malignancy.

Q: Does Atg-S affect my ability to drive or operate machinery?

A: Official information states that no specific studies have been performed to evaluate the effects on driving or operating machinery. However, caution is advised due to the potential risk of side effects such as dizziness or convulsion.

Q: What should I do if I notice a rash after starting Atg-S?

A: A rash can be a symptom of a delayed reaction, such as serum sickness, which typically appears several days after the infusion. If a rash or other new symptoms are observed, this is typically reported to the medical team for management.

Q: Is the medication supposed to be taken with food or on an empty stomach?

A: The medicine is not taken by mouth. According to administration guidelines, Atg-S is delivered intravenously (into a vein) as an infusion in a hospital setting. Therefore, instructions regarding taking it with food or on an empty stomach do not apply to this medicine.

Q: Are there any known interactions with birth control pills and Atg-S?

A: Official documents do not explicitly cite specific interactions between this drug and hormonal contraceptives (birth control pills). This aligns with the drug's properties as its large protein structure does not involve the major metabolic pathways responsible for interactions with many orally administered medicines.

Q: Can children or teenagers use Atg-S?

A: Official product information states that the safety and efficacy of Atg-S have not been established in controlled clinical trials for children or teenagers. The use of the drug in this population is therefore managed by specialist medical teams.

Q: Is Atg-S a biosimilar or a generic drug?

A: The medicine is officially classified as a polyclonal antibody preparation. This classification is distinct from both a generic (which is a small-molecule drug) and a biosimilar (which is a copy of a monoclonal antibody). The drug is derived from rabbit plasma, making it a xenotypic protein.

Q: Why does the official document mention a specific risk for people with kidney issues?

A: This information may be based on a misunderstanding of the official documentation. Official instructions specifically confirm that no dose adjustment is necessary for patients with renal (kidney) impairment, countering the implication that a specific risk is mentioned.

How should Atg-S be stored and disposed of?

The storage and disposal requirements for Antithymocyte Globulin (Rabbit) (ATG-S) are explicitly defined to maintain the product's quality and ensure proper handling.

Official Storage Conditions

Aspect Requirement
Temperature Store the lyophilized powder in a refrigerator at 2 C to 8 C (36 F to 46 F).
Protection The vials must be protected from light and must not be frozen.
Container Store in the original container to maintain integrity.

Stability and Handling

The reconstituted solution is physically and chemically stable for up to 24 hours when stored at 2 C to 8 C. However, because the reconstituted product contains no preservatives, regulatory documents recommend immediate use. The total storage time from reconstitution to administration should not exceed 24 hours.

Disposal Instructions

Any unused portion of the reconstituted or diluted drug must be discarded. Disposal of unused product and waste material must be done in accordance with local requirements for pharmaceutical waste. Like all medicines, ATG-S must be kept out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Atg-S found in:

A-Z Index: